About the debate
After very persuasive arguments from both sides, the judges awarded victory to the Cambridge team (proposition) this year. A key area of contention was in the safety of the nootropic drugs, with Oxford arguing that regulation was undermined by the lack of solid data on the effects of such drugs taken for solely nootropic benefit. Cambridge argued, on the other hand, that the safety and efficacy of consumption would be improved by their availability under prescription from doctors, and that the state had a duty to provide assistance to those who legitimately required the drugs for nootropic related reasons.